Three-Pillar Sourcing: Direct GMP Partnerships, PLPI and European Buying Networks

Resilience is a portfolio property

A supply chain is not resilient merely because it has several supplier names. Those suppliers may depend on the same manufacturer, country, regulatory pathway, logistics route or active ingredient. Genuine optionality requires the organisation to understand where the dependencies sit and to develop alternatives that can be activated lawfully and practically.

NovaPharm's three-pillar strategy separates sourcing into direct relationships with qualified GMP manufacturers, product-specific PLPI pathways and a European buying network of authorised organisations. The value is not that one pillar is universally better. Each has different evidence, lead time, economics and risk. Managed together, they can create more informed choices about how a suitable product opportunity should progress.

Pillar one: direct qualified manufacturing relationships

Direct manufacturer engagement can support technical understanding, capacity planning, quality agreements and a longer-term product strategy. For NovaPharm, the initial geographic emphasis is on suitable MHRA/EU-GMP-aligned manufacturers in India, reflecting the founder's experience and the depth of pharmaceutical capability in that market.

The relationship must be qualified for the actual product and route. A certificate alone does not establish that a facility, dosage form, market authorisation, import pathway or commercial arrangement is suitable for the United Kingdom. Technical due diligence may cover facility and authorisation scope, product development evidence, manufacturing process, analytical controls, stability, data integrity, deviations, inspection history, capacity, continuity and change notification.

A direct route may offer closer coordination, but it can require substantial regulatory, technical and working-capital preparation. The portfolio should not assume that a manufacturer relationship creates a UK saleable product. Rights, authorisations, qualified import and distribution functions, packaging and released inventory remain separate conditions.

Pillar two: product-specific PLPI strategy

The parallel-import route provides a distinct regulated pathway for appropriate EEA-authorised medicines. It requires an MHRA product-specific licence and the relevant company and site authorisations. The opportunity assessment must identify the UK cross-referenced product, application category, source evidence, company functions, packaging and labelling work, pharmacovigilance and recall obligations.

This pillar can create an additional sourcing option where the product, source and economics support it. It can also become unviable if source pricing changes, evidence is incomplete or ongoing variation requirements outweigh the opportunity. PLPI should therefore sit inside the same product-governance process as direct sourcing, with status labels that distinguish screening, regulatory preparation, licence grant, operational readiness and actual stock.

Pillar three: a qualified European buying network

A European buying network can widen access to authorised manufacturers, distributors and licensed wholesalers. NovaPharm's planned network focuses initially on Germany, the Netherlands, Poland and Romania. Those markets have different supplier landscapes and commercial characteristics; country names are not a substitute for organisation-level qualification.

The network should record each supplier's legal identity, authorisation, site, approved scope, product relationship, quality evidence, agreement status and performance. It should also identify indirect dependencies. Two wholesalers may buy from the same upstream source. A lower price may carry allocation, lead-time, transport or documentation risk. The commercial model needs to show landed cost and working-capital exposure, not only the quoted unit price.

One governance model across three channels

Diversification can increase complexity if every channel uses different records and approval criteria. The control objective is a shared product and supplier model. Each opportunity should have one identifier connecting the product concept, source organisations, regulatory route, technical evidence, quality decision, agreements, cost model and approval history.

Common stage gates make comparison possible. An opportunity enters screening, moves through confidentiality and evidence collection, receives technical, regulatory, quality and commercial assessments, and proceeds to contracting and operational readiness only when the required conditions are met. Decision makers can compare routes without lowering the standard for a seemingly urgent source.

• Use common supplier and product qualification criteria.
• Record route-specific regulatory requirements explicitly.
• Model landed cost and downside scenarios consistently.
• Identify shared upstream and logistics dependencies.
• Maintain approved alternatives before a disruption occurs.

Design failover before it is needed

A backup source is useful only if the organisation understands how it would be activated. The alternative may need a different licence, variation, customer approval, quality review, artwork, transport route or lead time. A resilience plan should state the trigger, responsible decision maker, minimum evidence, expected time and customer communication route.

Scenario exercises can test whether the records and relationships are real. What happens if a manufacturer stops production, a source wholesaler is allocated, a batch is held, a transport lane is unavailable or a regulatory change affects the presentation? The exercise should reveal which products lack an authorised alternative and where additional safety stock, supplier work or customer planning may be justified.

A strategy in development

NovaPharm's three-pillar model is a strategic architecture under development. The company does not claim that a target manufacturer, European supplier, PLPI licence or medicine is approved or available merely because it appears in the business plan. Each relationship and product must earn its status through due diligence, agreement and applicable authorisation.

That distinction is central to the model's credibility. The aim is not to maximise the number of sourcing routes shown on a slide. It is to build a governed portfolio in which direct manufacturing, parallel import and European buying can be evaluated honestly, connected to the same quality system and used to improve continuity when the evidence supports them.

Resilience then becomes measurable: fewer unknown dependencies, clearer alternatives, better data and faster controlled decisions. The three pillars are the structure. Qualification and governance are what make the structure useful.

Portfolio review should take place at a regular cross-functional forum. Regulatory, quality, sourcing, finance and commercial owners can examine evidence age, supplier concentration, route status, expected demand and unresolved risks. Decisions should include an owner and next review date. This prevents opportunity lists from growing without accountability and gives leadership a credible view of which relationships are exploratory, which are qualified and which could support an authorised launch.